Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Orbis Medicines signed a drug-discovery and licensing agreement with Novo Nordisk worth up to $1.4 billion. The collaboration will develop oral therapies for cardiometabolic diseases typically treated with injectable drugs, expanding Novo Nordisk's potential pipeline in a major treatment market.